AR019807A1 - Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh - Google Patents

Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh

Info

Publication number
AR019807A1
AR019807A1 ARP980106619A ARP980106619A AR019807A1 AR 019807 A1 AR019807 A1 AR 019807A1 AR P980106619 A ARP980106619 A AR P980106619A AR P980106619 A ARP980106619 A AR P980106619A AR 019807 A1 AR019807 A1 AR 019807A1
Authority
AR
Argentina
Prior art keywords
insoluble
composition
insulin
prepare
compositions
Prior art date
Application number
ARP980106619A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR019807A1 publication Critical patent/AR019807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP980106619A 1997-12-23 1998-12-22 Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh AR019807A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6860197P 1997-12-23 1997-12-23
US8885998P 1998-06-11 1998-06-11
US10994098P 1998-11-25 1998-11-25

Publications (1)

Publication Number Publication Date
AR019807A1 true AR019807A1 (es) 2002-03-20

Family

ID=27371371

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106619A AR019807A1 (es) 1997-12-23 1998-12-22 Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh

Country Status (24)

Country Link
US (2) US6531448B1 (de)
EP (1) EP0925792B1 (de)
JP (1) JP2001526225A (de)
KR (1) KR20010024799A (de)
CN (1) CN1284876A (de)
AR (1) AR019807A1 (de)
AT (1) ATE264690T1 (de)
AU (1) AU2008899A (de)
BR (1) BR9814471A (de)
CA (1) CA2315300A1 (de)
CO (1) CO4970787A1 (de)
DE (1) DE69823319D1 (de)
DZ (1) DZ2691A1 (de)
EA (1) EA003394B1 (de)
HR (1) HRP20000427A2 (de)
HU (1) HUP0100243A3 (de)
ID (1) ID25476A (de)
IL (1) IL136724A0 (de)
NO (1) NO20003269L (de)
NZ (1) NZ505091A (de)
PE (1) PE20000106A1 (de)
PL (1) PL341300A1 (de)
TR (1) TR200001935T2 (de)
WO (1) WO1999032116A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2002359730A1 (en) * 2001-12-21 2003-07-30 Smithkline Beecham Corporation Compositions and methods for altering glucose production
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
BR0317888A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
WO2004080481A1 (en) * 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
EP1620465A2 (de) * 2003-04-29 2006-02-01 Eli Lilly And Company Insulin-analoge mit zeitverzögerter wirkung
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
EP2626368B1 (de) * 2004-07-19 2016-12-21 Biocon Limited Insulinoligomerkonjugate, Formulierungen und Verwendungen davon
AU2014200247B2 (en) * 2004-07-19 2015-05-14 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
PL373543A1 (pl) * 2005-03-10 2006-09-18 Instytut Biotechnologii i Antybiotyków Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy
EP1916997B1 (de) * 2005-08-05 2018-04-18 Amgen Inc. Pharmazeutische formulierungen aus stabilen wässrigen proteinen und ihre herstellung
WO2007026474A1 (ja) * 2005-08-29 2007-03-08 Ajinomoto Co., Inc. 栄養組成物
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2049149B1 (de) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylierte verlängerte insuline
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (de) * 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmazeutische formulierung enthaltend ein insulinderivat
AU2008313248B2 (en) * 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (de) 2008-03-18 2016-10-05 Novo Nordisk A/S Proteasestabilisierte, acylierte insulinanaloga
WO2009125423A2 (en) * 2008-04-07 2009-10-15 National Institute Of Immunology Compositions useful for the treatment of diabetes and other chronic disorder
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
BRPI0919946A2 (pt) * 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
RU2012123642A (ru) 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2012171994A1 (en) * 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
GB2513805B (en) * 2012-04-18 2020-04-01 Waters Technologies Corp Methods for quantifying polypeptides using mass spectrometry
AU2013255880B2 (en) * 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2931301B2 (de) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Verfahren zum reinigen von insulin und analoga davon
WO2014096985A2 (en) * 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CA2937532A1 (en) * 2013-01-22 2014-07-31 Case Western Reserve University N-terminal truncated insulin analogues
CN103145829B (zh) * 2013-03-29 2015-06-03 江苏诺泰制药有限公司 一种地特胰岛素的纯化方法
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법
CN114306577B (zh) * 2020-10-10 2024-04-09 南京汉欣医药科技有限公司 一种门冬胰岛素30混悬液的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3012077A (en) * 1960-03-11 1961-12-05 Union Carbide Corp Process for the production of organo sulfur compounds
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
US4601979A (en) 1981-09-15 1986-07-22 Nordisk Insulinlaboratorium Process for preparing human insulin or B-30 esters thereof
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
EP0425482B1 (de) 1988-07-20 1993-08-18 Novo Nordisk A/S Menschliche insulinanalage und zubereitungen daraus
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
AT400337B (de) * 1990-05-02 1995-12-27 Plasser Bahnbaumasch Franz Gleisstopfmaschine mit in gleisquerrichtung verstellbaren stopfeinheiten
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
DK0705275T3 (da) 1993-06-21 1999-09-20 Novo Nordisk As AspB28-insulin-krystaller
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AU720966B2 (en) 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
DE69737995T2 (de) 1996-06-20 2008-04-24 Novo Nordisk A/S INSULINPREPARATION MIT MAnnitol
ES2242270T3 (es) 1997-02-07 2005-11-01 Novo Nordisk A/S Cristalizacion de proteinas.
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
CN1276731A (zh) 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea

Also Published As

Publication number Publication date
BR9814471A (pt) 2000-10-10
EP0925792A2 (de) 1999-06-30
NO20003269L (no) 2000-08-23
ID25476A (id) 2000-10-05
EA200000708A1 (ru) 2000-12-25
ATE264690T1 (de) 2004-05-15
CA2315300A1 (en) 1999-07-01
TR200001935T2 (tr) 2000-12-21
HUP0100243A3 (en) 2001-09-28
NZ505091A (en) 2002-11-26
DZ2691A1 (fr) 2003-03-29
CN1284876A (zh) 2001-02-21
HRP20000427A2 (en) 2001-06-30
IL136724A0 (en) 2001-06-14
EA003394B1 (ru) 2003-04-24
EP0925792A3 (de) 2001-09-12
KR20010024799A (ko) 2001-03-26
EP0925792B1 (de) 2004-04-21
JP2001526225A (ja) 2001-12-18
PL341300A1 (en) 2001-04-09
US20030144181A1 (en) 2003-07-31
NO20003269D0 (no) 2000-06-22
PE20000106A1 (es) 2000-02-09
AU2008899A (en) 1999-07-12
DE69823319D1 (de) 2004-05-27
CO4970787A1 (es) 2000-11-07
US6531448B1 (en) 2003-03-11
WO1999032116A1 (en) 1999-07-01
HUP0100243A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
AR019807A1 (es) Composiciones insolubles utiles para controlar la glucosa sanguinea, formulaciones en suspension que comprenden como fase insoluble dicha composicion;procedimiento para preparar dicha composicion insoluble y el uso de dichas composiciones insolubles para preparar medicamentos para el tratamiento deh
AR020047A1 (es) Composiciones insolubles de insulina, formulaciones en suspension que incluyen dicha composicion insoluble de insulina; y el uso de dicha composicionpara preparar medicamentos y procedimiento para preparar dichas composiciones insolubles.
KR960000923A (ko) 단량체성 인슐린 유사체의 제제
ES2360505T3 (es) Preparados de insulina libre de zinc o con bajo contenido en cinc con estabilidad mejorada.
JPS6042334A (ja) 糖尿病治療用薬剤
US8501440B2 (en) Fibrillation-resistant insulin and insulin analogues
TR201815158T4 (tr) Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri.
BR9407508A (pt) Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
ES2917893T3 (es) Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
KR920700226A (ko) 선형 소마토스타틴 유사체
NZ514609A (en) Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
UA26874C2 (uk) Пареhтеральhа фармацевтичhа композиція
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
RU2010133233A (ru) Новые производные инсулина с сильно замедленным профилем время/действие
IL128274A (en) Long-acting drugs and pharmaceutical compositions comprising them
EP1506230A1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
JP2013545782A (ja) 長時間作用型インスリンと組み合わせた速効型インスリン
MX2012000304A (es) Preparaciones insulinicas que comprenden metionina.
JPH02101022A (ja) 糖尿病治療用医薬組成物
DD298788A5 (de) Neue insulinverbindungen
ES2180511T3 (es) Formulaciones monodispersas de analogos de insulina acilados hexamericos.
KR20000022031A (ko) Nacl을 함유하는 인슐린 제제
BRPI0507177A (pt) agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso
John Basal insulin analogues--A review of recent data on efficacy and safety

Legal Events

Date Code Title Description
FB Suspension of granting procedure